(Boursier.com) — OSE Immunotherapeutics SA announces the publication, in the journal ‘Frontiers in Immunology’, of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation.
The ChemR23 receptor, or ‘chemerin chemokine-like receptor 1’ (CMKLR1), a G-protein coupled receptor (GPCR), is the target of OSE-230 expressed by tumor-associated macrophages (TAM), the most frequently tumor-infiltrating immune cells known to modulate chronic pro-tumor inflammation. Research has demonstrated that through activation of ChemR23, OSE-230 reprograms TAM cells. The ChemR23 receptor strongly controls the macrophage phenotype and its activation by OSE-230 leads to a significant remodeling of the immune tumor microenvironment by limiting the immunosuppressive functions of macrophages, by activating the activity of T lymphocytes and modifying the metastatic niche.
“Research carried out jointly with the CRCI2NA laboratory in Nantes (principal investigators: Christophe Blanquart and Sophie Barille) demonstrated the long-term efficacy of OSE-230 through the strong expression of ChemR23 in a model of severe chronic inflammation. With the decrease in the occurrence of metastases and the extension of overall survival, these data support the durability of the agonist effect of OSE-230 on severe chronic inflammation. These data make OSE-230 230 a first-in-class candidate for more advanced preclinical studies and pave the way for many indications of chronic inflammatory diseases, thanks to the significant advantages of the product compared to immunosuppressive treatments”, comments Aurore Morello, Research & Development Director of OSE Immunotherapeutics.
©2023 Boursier.com